Brandon White is a co-founder and CEO at Axiom Bio developing reasoning agents for drug predictions.
Based on 4 scored articles
Referenced in coverage
“Reports that GPT-5.5 delivered significant accuracy gains on drug discovery evals using their biochemical datasets.”
“Co-Founder and CEO at Axiom Bio who highlighted GPT-5.5's ability to predict drug outcomes and deliver accuracy gains on drug discovery evaluations.”
“Praised GPT-5.5 for delivering significant accuracy gains on drug discovery evals when applied to biochemical datasets.”
“Co-authored analysis of UAT-10608 threat cluster exploiting CVE-2025-55182 to harvest credentials from 766 hosts.”